Eli Lilly bolsters infectious disease portfolio with acquisitions totalling $3.8bn

CE2026-05-27T11:39:00

Source:

Investments in Curevo, LimmaTech Biologics and Vaccine Company set to advance vaccines for shingles, AMR-driving pathogens and Epstein-Barr Virus.

Eli Lilly is building on its investments in differentiated technology platforms with the acquisition of three vaccines-focused acquisitions, for a potential sum of $3.8 billion.

The three companies, Curevo, LimmaTech Biologics AG and Vaccine Company, all target viral pathogens linked to long-term neurological and oncological risk and bacterial pathogens that are difficult to prevent or treat. Lilly’s purchase of these biotech companies expand its R&D efforts into infectious disease.

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

Unlimited access to industry intelligence that can make a difference to your business
A weekly newsletter keeping the most vital information at the front of your thinking
Exclusive invitations to powerful webinars and events featuring high profile experts
Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member